Chemomab Therapeutics Ltd.

CMMB
$1.55 (+ $0.05 + 2.99%)
Last updated: 2026-06-18 15:50 UTC
CMMB Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS16385C1045
CUSIP16385C104
Market Price1.55
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-1.44
Market Cap$11.1M
Book Value1.82
Price to Book0.986
Beta0.55
52w High9.84
52w Low1.71
Next Earnings DateN/A

Chemomab Therapeutics Ltd. trades under ticker CMMB on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US16385C1045, CUSIP 16385C104.

About the Company
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.
Price History